Stem Cell Therapy Could Help Type 1 Diabetes Patients
A new stem cell-derived treatment may help adults with type 1 diabetes reduce their insulin use and improve glucose control.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Do you trust that new medical therapies can significantly reduce the emotional burden of managing diabetes?
A clinical trial of the stem cell-derived therapy zimislecel shows potential for managing type 1 diabetes by restoring natural insulin production. Twelve participants with high-risk hypoglycemia achieved improved glucose control and reduced their reliance on exogenous insulin.
Why it matters
This development represents a potential shift in type 1 diabetes management, moving from constant insulin monitoring to restored autonomous glucose regulation. For patients experiencing severe hypoglycemic episodes, the therapy may offer a way to regain glycemic stability.
In a Phase 1 and 2 trial of 12 adults with type 1 diabetes and impaired hypoglycemia awareness, participants treated with zimislecel achieved 93.3% time in range at one year. Findings remain preliminary as researchers continue to evaluate safety and long-term efficacy.
The players
University of Pennsylvania
An academic medical research institution where investigators have been studying the impact of islet cell transplantation on diabetes outcomes.
The details
Zimislecel is a stem cell-derived therapy that functions by replenishing the body's insulin-producing islet cells. Administered as a single infusion, it enables the pancreas to resume autonomous glucose regulation. To prevent the immune system from rejecting these transplanted cells, participants must also undergo a regimen of immunosuppressive therapy.
Timeline
90 days post-treatment, participants reached 76.1% time in glucose range.
180 days post-treatment, participants reached 88.3% time in glucose range.
1 year post-treatment, participants reached 93.3% time in glucose range and saw decreased psychological distress.
2025: Phase 1 and 2 data was presented at the ADA Scientific Sessions.
Health Landscape
The FORWARD-VX-880-101 trial advances the field of regenerative medicine by exploring alternatives to lifelong exogenous insulin reliance. This study aligns with the broader historical effort to move from glucose management to true biological restoration for patients with type 1 diabetes.
While promising, this therapy requires a conversation with your endocrinologist regarding the trade-offs of immunosuppression versus standard insulin management. Patients should continue current glucose monitoring protocols while awaiting larger, longer-term studies on safety.
The takeaway
Zimislecel offers a potential future where the body regulates its own glucose, significantly reducing the fear of dangerous hypoglycemia. For now, focus on maintaining glycemic targets with your current treatment plan and discuss clinical trial updates with your diabetes care team.
Further reading
For more on evolving research, visit our Diabetes section.
Live Poll
Do you trust that new medical therapies can significantly reduce the emotional burden of managing diabetes?
